Eagle Pharmaceuticals Inc buy klostergang
Start price
23.06.15
/
50%
€77.64
Target price
23.12.15
€95.00
Performance (%)
9.73%
End price
23.12.15
€85.20
Summary
This prediction ended on 23.12.15 with a price of €85.20. The BUY prediction by klostergang finished with a performance of 9.73%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Eagle Pharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | 0,30 % | 4,70 % | 4,54 % | 51,55 % |
| iShares Nasdaq 100 | 0,43 % | 12,26 % | 31,98 % | 98,29 % |
| iShares Nikkei 225® | 1,63 % | 12,62 % | 43,26 % | 69,87 % |
| iShares S&P 500 | 0,57 % | 7,79 % | 23,48 % | 69,79 % |
Comments by klostergang for this prediction
In the thread Eagle Pharmaceuticals Inc diskutieren
Fly like :
- Eagle Pharmaceuticals (NASDAQ:EGRX) submits a New Drug Application (NDA) to the FDA for a stable liquid intravenous formulation (ready-to-use or RTU) of bivalirudin for the treatment of patients undergoing percutaneous coronary intervention (PCI) in the following scenarios: with the use of a glycoprotein IIb/IIIa inhibitor or at risk of heparin-induced thrombocytopenia and thrombosis syndrome and patients with unstable angina undergoing percutaneous transluminal coronary angioplasty.
- RTU bivalirudin, intended for use with aspirin, contains the same active ingredient as The Medicines Company's (NASDAQ:MDCO) Angiomax (bivalirudin), but eliminates the need for reconstitution/dilution.
- Angiomax generated ~$600M in sales in 2014.
- Bivalirudin is an anticoagulant that inhibits thrombin.
(Laufzeit überschritten)